Here is a strange fact about hepatitis C. It is one of the few chronic viral infections that medicine can actually cure, and the cure is a short course of pills. Yet the CDC estimates that 2.4 to 4 million people in the US were living with the virus during 2017 to 2020, and most of them do not know it. In 2023 doctors reported 4,966 new acute cases, but the CDC believes the real number was closer to 69,000. The virus usually causes no symptoms, so it stays hidden.
So the hepatitis C story today is not about finding a cure. It is about a cure that already exists and millions of people it has not reached yet. This guide covers what is approved right now, what researchers are testing, why progress looks so different in this field than in others, and where clinical trials fit in.
Looking for treatment options for Hepatitis C?
Browse open Hepatitis C clinical trials near you! We'll handle the follow-up.
What's approved right now
Modern hepatitis C treatment is built around a type of drug called direct-acting antivirals, or DAAs. The name says it all: they act directly on the virus. You take them as pills, usually for 8 to 12 weeks, and they cure more than 95 out of 100 people. That works across all 7 known strains of the virus, which matters a lot, since older treatments only worked on some strains. Doctors call this "pangenotypic," and it's the reason doctors today rarely need to figure out exactly which strain you have before starting treatment.
FDA-approved treatments currently on the market:
- Mavyret (glecaprevir and pibrentasvir, AbbVie). In June 2025, the FDA expanded its approval, making it the first and only treatment for acute hepatitis C, the early stage right after infection. That means doctors can now start treatment right at diagnosis, instead of waiting for the infection to become chronic. The course takes 8 weeks.
- Epclusa (sofosbuvir and velpatasvir, Gilead). A 12-week treatment that works across all virus strains. It's also the benchmark that new drugs get measured against in trials.
- Harvoni (ledipasvir and sofosbuvir, Gilead).
- Vosevi (sofosbuvir, velpatasvir and voxilaprevir, Gilead). Currently being studied for people whose earlier treatment didn't clear the virus.
- Sovaldi (sofosbuvir, Gilead).
- Zepatier (elbasvir and grazoprevir, Merck).
- Ribavirin, an older antiviral, is still used as an add-on treatment in some cases.
Several earlier treatments, like Viekira Pak, Olysio, Daklinza, Incivek, and Victrelis, were taken off the market. Not because they failed, but because newer drugs that work on every strain made them unnecessary. That's actually pretty rare in medicine: an entire generation of drugs getting fully replaced within about a decade.
One more important thing: there's no vaccine for hepatitis C. Vaccines exist for hepatitis A and B, but not C. Testing and treatment are the only tools we have right now.
Can children be treated too?
Yes, starting at age 3. Curative treatment is FDA-approved for anyone 3 years and older, and major medical guidelines recommend treatment for everyone with hepatitis C, except pregnant women and children under 3. That age cutoff matters because for young kids, the main way they get infected isn't through needles, it's through birth. About 6 to 7 out of every 100 babies exposed during pregnancy or delivery end up infected, and researchers estimate roughly 1,700 infants are born with hepatitis C in the US each year. Some of these children clear the virus on their own in their first few years of life, which is part of why the CDC recommends a specific test at a specific age rather than treating right away: since October 2023, every exposed baby should get a viral (RNA) test between 2 and 6 months old. And breastfeeding doesn't increase the risk of passing on the virus, unless the mother's nipples are cracked or bleeding.
What researchers are testing now
For years, the hepatitis C drug pipeline was quiet. A 95% cure rate is a hard thing to improve on. That started to change in 2026.
A new two-drug combination passed a major trial stage. Atea Pharmaceuticals is developing bemnifosbuvir and ruzasvir, a once-daily pill combination. In July 2026, the company announced that its main North American trial, called C-BEYOND, met its goals. The new combination cured about 94 out of 100 people, which is basically the same result as Epclusa, the current standard treatment, which cured about 95 out of 100 people in that same study of roughly 900 participants. The real difference: in people without cirrhosis, the new combination did this in 8 weeks instead of Epclusa's 12. A second global trial, called C-FORWARD, finished enrolling participants in June 2026. If that one succeeds too, this would be the first genuinely new hepatitis C treatment in years. It's worth noting what the actual goal was here, though. Not a higher cure rate, since there's barely any room to improve above 95%. Just a shorter treatment time, for the same result.
Most other studies aren't about new drugs at all, they're about reaching people. As of August 2026, there are 55 hepatitis C studies recruiting, and most of them aren't drug trials. Instead, they're focused on finding people who are infected and getting them the cure that already exists. Common themes include treatment through telemedicine, care led by pharmacists, testing done on the spot, treatment during pregnancy, programs inside jails and prisons, and care built into opioid treatment programs. There's also a line of research involving organ transplants, where organs from donors who had hepatitis C are given to patients, who then take antiviral medication afterward. Baylor Research Institute is running the Hepatitis C Transplant Collaborative, a 500-person study of this approach, currently recruiting. This idea would have sounded crazy before these drugs existed: deliberately transplanting an organ from someone who had the virus, because the recipient can simply be cured afterward. It only works because the cure is that reliable.
Researchers involved in this field range widely, from AbbVie and the NIH to Johns Hopkins, Columbia, the University of Washington, and Oxford. The Kirby Institute is studying opioid treatment settings, and the Task Force for Global Health keeps a registry tracking treatment during pregnancy. Looking at that list, the pattern becomes clear: this is mostly public health research, funded by universities and governments, not a competition between drug companies trying to build something new.
Why hepatitis C research works differently now
The comparison problem. You can't test a new hepatitis C drug against a placebo. A cure already exists, so withholding it from someone in a study would be unethical. Instead, new drugs get tested head to head against an already-approved treatment, and they have to match its results. That's a tough bar, since the existing treatment already cures more than 95 out of 100 people, leaving almost no room to improve. This is also why these trials use such a precise finish line. It's called SVR12 (sustained virologic response at 12 weeks), which just means no virus can be found in the blood 12 weeks after finishing the pills. Regulators count that as a cure, so a new drug basically has to hit that same number as the older ones.
The reach problem. Most people with hepatitis C don't know they have it. Just compare the numbers: doctors reported 4,966 new cases in 2023, but the CDC estimates the real number was closer to 69,000. You can't treat, or cure, someone who's never been diagnosed in the first place. That's exactly why the CDC recommends everyone get tested at least once, and why pregnant women get tested during every pregnancy, and why so many current studies aren't really about new drugs, they're about finding people and connecting them to care. West Virginia University is testing one version of this idea with a mobile clinic that visits rural areas, testing 200 people for HIV, hepatitis C, and syphilis right there on the spot, instead of waiting for people to come into a clinic. The logic is simple, if a little sad: if patients won't come to the healthcare system, bring the healthcare system to them.
The representation problem. The groups hit hardest by hepatitis C, people who inject drugs, people in prison, and pregnant women, have historically been left out of research. That's starting to change. These groups are now the main focus of a lot of current studies, from telehealth programs that reconnect people who use drugs with treatment, to a global registry tracking hepatitis C treatment during pregnancy. Pregnancy is the clearest example of this gap: current treatment guidelines still exclude pregnant women, so researchers need to build up solid evidence through registries and dedicated studies before that can change. Curious what it actually looks like to volunteer for a study like this?
What does a hepatitis C rash look like?
This question comes up a lot, and the honest answer is: a rash isn't actually on the CDC's official list of hepatitis C symptoms. What is true is that long-term infection is linked to a few specific skin conditions, and sometimes the skin is where people first notice something's wrong.
The most studied connection is something called mixed cryoglobulinemia. Basically, certain proteins clump together in the blood when it gets cold, and those clumps can cause inflammation in small blood vessels. These proteins actually show up in 40 to 60 out of 100 people with hepatitis C, which sounds concerning until you see the next number: only 5 to 10 out of 100 people actually go on to develop the vessel inflammation itself. When it does affect the skin, it usually looks like small purple-red raised spots, or tiny pinpoint dots called petechiae, most often on the lower legs. Researchers have found that treating the underlying virus actually reduces these skin symptoms.
The other known connection is a condition called porphyria cutanea tarda, which causes blisters, sores, and fragile skin on sun-exposed areas like the backs of the hands. About half of people with this condition also have hepatitis C, which is common enough that doctors recommend testing for the virus whenever it's diagnosed. Lichen planus (a different skin condition) has also been linked to hepatitis C, though how strong that connection is seems to vary by region.
None of this means a rash is a reason to assume you have hepatitis C. But it does mean skin changes are worth mentioning to your doctor, especially since the CDC already recommends everyone get tested for hepatitis C at least once anyway.
Common myths
"Hepatitis C can't be cured."
This used to be true, but not anymore. Modern antiviral pills cure more than 95 out of 100 people in just 8 to 12 weeks. A lot of people still picture hepatitis C as a lifelong disease, and that outdated idea ends up costing them years of walking around with an infection that could've been easily treated.
"Only people who use drugs get it."
Injection drug use is the most common risk factor today, but it's far from the only one. People who got blood transfusions before 1992 were exposed before blood donors were screened for the virus. It can also pass from a mother to her baby, and less commonly, through sex. Because of this, the CDC recommends every adult get tested at least once, regardless of their personal history.
"You would know if you had it."
Actually, usually you wouldn't. Most infections cause zero symptoms for years, which is exactly how millions of people end up carrying the virus without ever knowing. When symptoms do show up, they usually appear 2 to 12 weeks after infection, and they can look like a lot of other things: tiredness, fever, joint pain, nausea, stomach pain, loss of appetite, dark urine, pale stools, and sometimes yellowing of the skin or eyes. The numbers from 2023 make this clear on their own: under 5,000 reported new cases, against an estimated 69,000 that actually happened.
"Hepatitis is hepatitis, the letters don't really matter."
Actually, the letters matter a lot. Hepatitis A, B, and C can look similar symptom-wise, but these three viruses spread differently and have very different outcomes. Hepatitis A spreads through close contact or contaminated food and water, and it's usually a short illness with full recovery and no lasting form. Hepatitis B spreads through blood, semen, and other body fluids, can become a long-term infection, and current medications only control it rather than cure it. Hepatitis C spreads through blood, and it's the one that's actually curable. The CDC sums up the whole difference in one simple line: vaccines can prevent hepatitis A and B, but medication can cure hepatitis C.
The stages of hepatitis C, and what care usually looks like
Acute infection. This is the first stage after the virus enters the body, roughly the first six months. Most people feel nothing at all, and those who do usually notice symptoms 2 to 12 weeks in. Doctors test for this stage using an RNA test rather than an antibody test, because the virus itself can actually be detected as early as 1 to 2 weeks after exposure, while antibodies take longer to show up. Since the June 2025 approval of Mavyret, doctors can now treat this stage right away, an approach often called "test and treat."
Chronic infection. More than half of infected people don't clear the virus on their own, and the infection settles in for the long haul. This stage is usually silent, or shows up as nothing more specific than constant tiredness, which is exactly why it can go unnoticed for decades. Typical care here is a course of antiviral pills (DAAs) for 8 to 12 weeks. This is also the stage where most of the problems outside the liver, like the skin, kidney, and metabolic issues mentioned earlier, tend to show up.
Cirrhosis. Years of untreated infection can scar the liver over time. Care at this stage usually still includes antiviral medication, but doctors watch the liver more closely since cancer risk goes up. Cirrhosis is also an important dividing line in clinical trials: many drug studies only enroll people who don't have cirrhosis, or use a different treatment length for those who do, which is why the 8-week result from the Atea trial mentioned earlier specifically applied to people without cirrhosis.
Liver cancer. For people with cirrhosis, the risk of liver cancer is 1 to 4 in 100 each year. At this stage, care shifts to cancer specialists, and transplant medicine can become part of the picture, which is one reason transplant research is such an active area in hepatitis C right now.
These are just descriptions of typical care, not personal medical advice. Your own treatment plan should be worked out with your doctor.
How to find a hepatitis C clinical trial
AllClinicalTrials.com lists hepatitis C studies that are recruiting now, from antiviral trials to testing and treatment programs. Right now that mix runs from rapid screening in a rural street medicine clinic to transplant protocols using organs from donors who had the virus. There's also a pharmacist-led hepatitis C management program in Toronto, testing whether pharmacists can take on more of the care that usually falls to a doctor's office. You can browse studies by location and study type, and the application takes about 5 minutes. If a study looks like a fit, the research team contacts you and walks you through the next steps, including informed consent, before you commit to anything.
Common questions
What is hepatitis C, in simple terms? It is a liver disease that comes from a bloodborne virus, HCV. The virus usually works quietly, so someone can carry it for a long time with nothing to notice, and it often turns up only when a blood test looks for it or the liver has already taken damage. And unlike most long term viral infections, this one can be cured with pills.
What is SVR12? It stands for sustained virologic response at 12 weeks, meaning no virus can be found in the blood 12 weeks after treatment ends. Trials and doctors use it as the definition of cure.
Is there a vaccine for hepatitis C? No. Vaccines exist for hepatitis A and B, but not for C. That makes testing and treatment the main tools against the virus.
Can hepatitis C come back after treatment? Cure means the virus is gone, and it does not return on its own. But treatment does not leave you immune, so a new exposure can cause a new infection. That is one reason follow up testing matters for people with ongoing risk.
How do doctors test for hepatitis C? Testing starts with a hepatitis C antibody test, a blood test that shows whether you were ever infected. A positive antibody result is followed by an RNA test, which shows whether the virus is still in your body right now. The RNA test can pick the virus up early, as soon as 1 to 2 weeks after exposure. Because most people have no symptoms, the CDC recommends that every adult get tested at least once, and that every pregnancy be tested.
How is hepatitis C transmitted? It spreads when blood from an infected person enters another person's body. In the US that happens most often through shared needles or other injection equipment, and before 1992 it happened through blood transfusions. Sexual transmission and passing the virus from mother to baby happen too, but less often. It is contagious only through blood, so hugging, coughing, sharing food, and kissing are not routes the CDC describes for it.